Palatin Technologies Stock Discussion

NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...

$Palatin Technologies (PTN.US)$
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Thursday, 19th December at 7:30 am
• Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
• Demonstrated efficacy at 6 months
◦ 71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr)
◦ 71% of patients achieved improved or stab...

$Palatin Technologies (PTN.US)$ Reuters· just
Palatin Announces Positive Phase Iib Breakout Study Results in Patients With Type 2 Diabetic Nephropathy! Palatin Technologies Inc - Bremelanotide Well Tolerated With No Serious Adverse Events

$Palatin Technologies (PTN.US)$
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
• Topline results expected in 1Q calendar year 2025
• Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weight
• Data will inform and support the Company's obesity programs using novel, long-acting and highly selective MC4R peptide and small molecule compoun...

$Palatin Technologies (PTN.US)$  so Happy buying $1.17 bottom of the year . look cheap to Happy Me .. squeezing  call it 😃👍💎✅🚀

$Palatin Technologies (PTN.US)$
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
• Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)
◦ Patient Dosing Commenced 3Q Calendar Year 2024
◦ Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024
◦ Topline Results Expected 1Q Calendar Year 2025
• Dry Eye...

$Palatin Technologies (PTN.US)$ Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
3 MINUTES AGO, 7:30 AM EDT
VIA PR NEWSWIRE
Dry Eye Disease (DED): PL9643
◦ MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies
▪ FDA Confirms Protocols and Endpoints
▪ Targeting Enrollment Start in 4Q Calendar Year 2024
▪ Topline Results Anticipated 4Q Calendar Year 2025
◦ Potential Collaboration/Funding Discussions Ongoing
• Obesity: Phase 2 Clinical Study ...